14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 300 days ( 32.59 % )
Last Price 20.64€ 0 %
High/ Low 20.64€ - 20.64€ 0%
Chg 7 Days N/A $20.64 20.64€
Chg 30 Days N/A $20.64 20.64€
Chg 12 mos -27.43 % $28.44 20.64€
Trend - 3 mos -0.0366 % Width: 2.32 %
Trend - 12 mos -35.09 % Width: 68.11 %
Pred. range - 3 mos 20.17€ - 20.63€ -2.30 % - -0.0371 %
Pred. range - 12 mos 8.80€ - 14.79€ -57.38 % - -28.35 %
Short MA avg 3 mos Buy Oct 03, 2023 - 59 days
Long MA avg 3 mos Buy Nov 10, 2023 - 31 days
Short/Long MA avg 3 mos Buy Nov 10, 2023 - 31 days
Short MA avg 12 mos Buy Oct 23, 2023 - 45 days
Long MA avg 12 mos Buy Nov 28, 2023 - 19 days
Short/Long MA avg 12 mos Buy Nov 28, 2023 - 19 days
Pivot Short Sell Dec 21, 2023 - 2 days
Bollinger Sell Nov 30, -1 - N/A days
MACD N/A No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About Bavarian Nordic A/S

Bavarian Nordic A/S Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine,... BV3.F Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT